Please assess the completion status of the following clinical trial:

Trial Title: Possible Use of Rotigotine in Subjects 70 Years and Older With Late Onset of Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥70 years~* Idiopathic Parkinson's Disease (PD) confirmed by at least two of the following signs: resting tremor, bradykinesia, rigidity~* Diagnosis of Parkinson's Disease (PD) within the last 12 months and onset of symptoms within 12 months from diagnosis~* Disease stage I or II according to Hoehn and Yahr Scale~* Ability to provide written informed consent~* Patients willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures~Exclusion Criteria:~* Disease duration more than 12 months since diagnosis and/or duration of symptoms at diagnosis for more than 12 months~* Hoehn \& Yahr stage ≥3~* Atypical or secondary parkinsonism~* Patient currently on L-dopa, Dopamine Agonist (DA) or other Parkinson's Disease (PD) medication at baseline~* Centrally acting dopaminergic agents, monoamine oxidase inhibitors (MAOIs), tolcapone, budipine, neuroleptics taken within the 28 days preceding the baseline visit~* History of deep brain stimulation~* History of severe cardiac disease/heart failure in the last 3 years~* History of repeated falls~* History of sulfite sensitivity~* Arterial hypotension~* Stroke or a transient ischemic attack within the last 12 months~* Previous or current treatment with rotigotine (at any time)~* Diagnosis of dementia according to Diagnostic and Statistic Manual (DSM)-IV-Revised~* Mini Mental State Examination (MMSE) total score \<24 at screening visit~* History of psychosis~* Clinically relevant hepatic dysfunction and/or transaminase levels 5+ times higher than upper normal value~* Experimental treatments within the antecedent 3 months~* History of drug or alcohol dependency~* Poor compliance with treatment~* Inability to comply with protocol

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rotigotine (Type: EXPERIMENTAL): 80 patients with late onset PD are randomized in 2 parallel groups, ratio 1:1.
- Placebo (Type: PLACEBO_COMPARATOR): 80 patients with late onset PD are randomized in 2 parallel groups, ratio 1:1.

Based on this trial design, predict the completion outcome and termination type (if applicable).